Core Viewpoint - Health元 emphasizes that short-term fluctuations in sales expenses are not indicative of long-term trends, and the company has seen a general decline in sales expense ratio due to improved management efficiency [2] Group 1 - The company highlights the importance of proactive academic promotion and market education for innovative drugs during their initial launch phase to help both doctors and patients understand their clinical value [2] - The company plans to continue optimizing resource allocation and enhancing operational efficiency to ensure that future investments yield sustainable returns [2]

（编辑 楚丽君） 证券日报网讯 健康元11月18日在互动平台回答投资者提问时表示，公司高度重视对投资者的回报，未 来将结合经营业绩、现金流状况、发展规划等多方面因素，统筹考量利润分配方案，力求在保障公司长 远发展的同时，合理回报广大投资者。 ...

Core Viewpoint - The company, JianKangYuan, is a comprehensive pharmaceutical enterprise deeply engaged in the medical field, with a diversified business layout that includes various sectors such as chemical preparations, biological products, chemical raw materials and intermediates, traditional Chinese medicine preparations, diagnostic reagents and equipment, and health foods [1] Group 1 - The company operates in multiple fields, forming a synergistic business layout [1] - Health products are only one of the business segments within the company's broader portfolio [1]

（文章来源：证券日报） 证券日报网讯健康元11月18日在互动平台回答投资者提问时表示，二级市场表现受多重因素综合影响， 公司始终将提升经营业绩、创造企业价值作为长期工作核心。 ...

（记者 王晓波） 每经AI快讯，有投资者在投资者互动平台提问：玛帕西沙韦（TG-1000）胶囊的上市审评目前处于正常 状态。审评过程中，监管部门要求补充核对标签说明书等相关文件，请问咱们补充材料是否提交，如果 没有提交大约什么时候提交材料。 健康元（600380.SH）11月18日在投资者互动平台表示，玛帕西沙韦（TG-1000）胶囊的上市审评目前 处于正常推进状态。对于审评过程中监管部门提出的补充核对标签说明书等相关文件的要求，公司高度 重视并已及时完成相关材料的整理与提交工作。后续，公司将持续与审评中心保持密切沟通，积极配合 各项审评工作，力争尽快推动产品审评流程有序推进。 ...

Core Insights - The flu season in China is expected to peak in late December and early January, leading to increased competition among flu medications [1][3] - Prices for flu medications, particularly for the popular drug Sufo, have started to drop as companies aim to capture market share [1][2] - The market for flu medications in China has surpassed 10 billion yuan, with Oseltamivir holding over 80% market share [4][5] Group 1: Market Dynamics - Sufo, a drug from Roche, was initially priced at 498 yuan per box but has seen a significant reduction to 222.36 yuan after being included in the national medical insurance directory [3] - The supply of Sufo is currently stable, with prices ranging from 239 to 258 yuan in retail pharmacies [2] - The entry of multiple domestic flu medications is intensifying competition, with several new products expected to launch in 2025 [6][7] Group 2: Competitive Landscape - Traditional flu medications like Oseltamivir are facing price pressures due to increased competition and collective procurement policies, with prices dropping significantly [4][5] - The market is seeing a surge in domestic flu drugs, with several companies like Qingfeng Pharmaceutical and Zhongsheng Pharmaceutical launching new products [6][8] - Oseltamivir's market share is projected to decline to 54.8% as more competitors enter the market, with over 70 companies producing the drug [5] Group 3: Regulatory and Development Updates - New flu medications are actively seeking inclusion in the medical insurance directory to enhance accessibility for patients [8] - Recent approvals for new flu drugs indicate a growing focus on pediatric formulations, with companies like Zhongsheng actively pursuing clinical trials for younger populations [7][8]

Investment Rating - The report maintains a rating of "Overweight" for the pharmaceutical and biotechnology sector [5]. Core Insights - The report highlights a significant increase in influenza-like illness (ILI) cases, suggesting a potential surge in demand for flu vaccines, respiratory virus testing, and cold medications [2][24]. - The report emphasizes the importance of clinical value in the pharmaceutical sector, advocating for investments in innovative drug chains and medical devices [3][27]. Summary by Sections Market Review - The pharmaceutical and biotechnology index rose by 3.29%, outperforming the CSI 300 index by 4.37 percentage points and the ChiNext index by 4.59 percentage points, ranking 5th among 31 sub-industries [1][16]. - The Hong Kong Hang Seng Medical Health Index increased by 6.8%, surpassing the Hang Seng Index by 5.4 percentage points [1][16]. Current Trends - The proportion of flu-like cases has been rising, with the ILI percentage reported at 5.5% in southern provinces and 6.1% in northern provinces, indicating a higher incidence compared to previous years [22][23]. - The report warns of a potential severe flu season in 2025, driven by changes in circulating strains and increased risks of immune evasion [2][23]. Investment Recommendations - The report suggests focusing on investment opportunities in flu vaccines, respiratory virus testing, cold medications, and special drugs due to the rising flu cases [2][24]. - Specific companies recommended for flu vaccines include Hualan Biological Engineering, Baike Biological, and Jindike; for respiratory virus testing, companies like Innotec, Shengxiang Biological, and Botao Biological are highlighted; and for cold medications, companies such as Zhongsheng Pharmaceutical, China Resources Sanjiu, and Kangyuan Pharmaceutical are suggested [2][24][26]. Key Company Earnings Forecast and Valuation - The report provides a detailed earnings forecast and valuation table for key companies, indicating a "Buy" rating for Tianjin Tasly Pharmaceutical, Innovent Biologics, and WuXi AppTec, among others [4][29]. - The earnings per share (EPS) and price-to-earnings (PE) ratios for these companies are projected to improve over the next few years, reflecting positive market sentiment [4]. Annual Investment Strategy - The report outlines a three-stage investment strategy focusing on clinical value, emphasizing the need for innovative drugs and high-end medical devices [3][27]. - It highlights the potential for growth in the innovative drug sector and the importance of domestic and international market dynamics [27][28].

证券代码：600380 证券简称：健康元 公告编号：临2025-075 健康元药业集团股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ●本次会议是否有否决议案：无 一、会议召开和出席情况 1、股东会召开的时间：2025年11月14日 2、股东会召开的地点：深圳市南山区高新区北区朗山路17号健康元药业集团大厦二号会议室 3、出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： （3）董事会秘书朱一帆先生现场出席，副总裁唐廷科先生、杜艳媚女士、张雷明先生以视频方式列 席。 二、议案审议情况 非累积投票议案 1、议案名称：《关于取消监事会、变更注册资本及修订〈公司章程〉部分条款的议案》 ■ 4、表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由公司董事会召集，经半数以上董事推举，董事林楠棋先生主持本次会议。本次会议以现场投 票及网络投票相结合的方式进行表决，会议的召集、召开和表决方式符合《公司法》、《上市公司股东 会规则》及《公司章 ...

证券日报网讯 11月14日晚间，健康元发布公告称，公司于2025年11月14日召开2025年第一次职工代表 大会，审议并通过《关于选举公司第九届董事会职工代表董事的议案》，选举杨颖女士为公司第九届董 事会职工董事。 （文章来源：证券日报） ...

北京德恒（深圳）律师事务所 关于《健康元药业集团股份有限公司章程》修订之 法律意见 深圳市福田区金田路 4018 号安联大厦 B 座 11 层 电话:0755-88286488 传真:0755-88286499 邮编:518026 ——————————————————————————— ——————————————————————————— 致：健康元药业集团股份有限公司 北京德恒（深圳）律师事务所（下称"本所"）受健康元药业集团股份有限公 司（下称"公司"）之委托，就公司经其 2025 年 11 月 14 日召开的 2025 年第二次 临时股东会审议通过的《关于取消监事会、变更注册资本及修订<公司章程>部 分条款的议案》（以下简称"《章程修订议案》"）的合法有效性出具法律意见书。 本所持有中华人民共和国司法部颁发的《律师事务所执业资格证书》，签发 本法律意见书的经办律师（下称"本所律师"）持有《中华人民共和国律师执业证》， 具备就上述《章程修订议案》出具法律意见的主体资格。 本法律意见书根据（包括但不限于）《中华人民共和国公司法》（下称"《公 司法》"）、《中华人民共和国证券法》（下称"《证券法》"）、《上 ...